Adage Capital Partners Gp, L.L.C. Xenon Pharmaceuticals Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,863,473 shares of XENE stock, worth $63.8 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
1,863,473
Previous 2,083,972
10.58%
Holding current value
$63.8 Million
Previous $82 Million
10.92%
% of portfolio
0.13%
Previous 0.15%
Shares
22 transactions
Others Institutions Holding XENE
# of Institutions
219Shares Held
66.7MCall Options Held
109KPut Options Held
2.1K-
Avoro Capital Advisors LLC New York, NY5.67MShares$194 Million3.24% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.52MShares$155 Million1.73% of portfolio
-
Braidwell LP Stamford, CT2.91MShares$99.8 Million6.4% of portfolio
-
Janus Henderson Group PLC London, X02.87MShares$98.2 Million0.06% of portfolio
-
Commodore Capital LP New York, NY2.74MShares$93.9 Million10.76% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.13B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...